Medicine and Dentistry
Adult
20%
Analysis
16%
Anti-biotics
15%
Antibiogram
8%
Antibiotic Therapy
6%
Antiinfective Agent
21%
Assessment
6%
Azithromycin
5%
Bacterium
15%
Breathing
7%
Bronchiectasis
20%
Burkholderia Cepacia Complex
7%
Chemotherapy
7%
Chest
5%
Child
7%
Chronic Obstructive Pulmonary Disease
10%
Clinical Trial
6%
Combination Therapy
5%
Consensus
5%
Culture
14%
Cystic Fibrosis
100%
Development
10%
Diseases
9%
Host
5%
In Vitro
13%
Infection
30%
Inflammation
6%
Inpatient
7%
Ivacaftor
10%
Lung
49%
Lung Clearance
11%
Lung Infection
7%
Methicillin Resistant Staphylococcus Aureus
7%
Microbiome
16%
Mortality
6%
Pathogen
21%
Patient
54%
Patient with Cystic Fibrosis
10%
Protein
6%
Pseudomonas aeruginosa
25%
Respiratory Tract Infection
8%
Respiratory Tract Inflammation
5%
Silo-Filler's Disease
8%
Species
7%
Sputum
34%
Survival
5%
Therapeutic Procedure
23%
Tissues
8%
Tobramycin
5%
Transplantation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Anaerobic Bacterium
5%
Antibiotic Agent
27%
Antibiotic Resistance
8%
Antibiotics
22%
Antiinfective Agent
73%
Antimicrobial Resistance
5%
Bacterium
21%
Biomaterial
6%
Bronchiectasis
8%
Burkholderia Cepacia Complex
7%
Carbon Tetrachloride
7%
Ceftazidime
10%
Chemotherapy
18%
Chronic Obstructive Lung Disease
8%
Cystic Fibrosis
84%
Drug
6%
Extended Spectrum Beta Lactamase
8%
Fosfomycin
7%
Gentamicin
7%
Implant
5%
Infection
35%
Infectious Agent
31%
Inhalation
5%
Lung Infection
9%
Methicillin-Resistant Staphylococcus Aureus
12%
Methylthioninium Chloride
8%
Microbiome
7%
Microflora
11%
Minimum Inhibitory Concentration
5%
Murepavadin
7%
Penicillinase
5%
Photosensitizer
8%
Polymer
5%
Prevotella
12%
Pseudomonas aeruginosa
45%
Respiratory Tract
7%
Staphylococcus
9%
Tetrazolium
7%
Tobramycin
26%
Virulence
5%
Immunology and Microbiology
Anaerobe
7%
Anaerobic Bacterium
15%
Antibiotic Sensitivity
15%
Antimicrobial Resistance
13%
Association
6%
Bacterium
18%
Biofilm
19%
Comprehension
5%
Density
6%
Development
5%
Gene
14%
Genus
9%
Growth
6%
Haemophilus influenzae
5%
Health
8%
Infectious Agent
18%
Inflammation
13%
Lung
60%
Lung Clearance
5%
Methicillin-Resistant Staphylococcus Aureus
5%
Microbiome
16%
Microflora
31%
Minimum Inhibitory Concentration
12%
Modulation
5%
Mortality
6%
Mutation
9%
Position
5%
Prevotella
11%
Pseudomonas
9%
Pseudomonas aeruginosa
34%
Reduction (Chemistry)
7%
Sample
36%
Species
16%
Sputum
38%
Streptococcus
9%
Taxon
18%
Time
10%
Tissues
6%
Total Viable Count
5%
Urine
6%
Veillonella
5%
Virulence
5%